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ABSTRACT 
Therapeutic implications of cholinergic anti-inflammatory pathway (CAP) activation have 
marked the beginning of a novel treatment strategy of passing electrical impulses along the 
left vagus nerve to alleviate acute and chronic inflammatory conditions. Extensive work in 
understanding CAP through vagus nerve stimulation (VNS) have identified key molecular 
and cellular mechanisms involved in the α7 nicotinic acetylcholine receptor (nAChR) 
mediated control of inflammation. Interestingly, recent studies have implicated a role of 
prostaglandin E2 (PGE2), whose concentration is increased locally following α7 nAChR 
activation, in this neuro-immune crosstalk. PGE2 is a potent lipid mediator produced by the 
action of cyclooxygenase enzymes (COX-1/2) and other specific downstream enzymes such 
as microsomal prostaglandin synthase-1 (mPGES-1) on the phospholipase-released 
arachidonic acid. While the role of PGE2 during inflammation is still debated, it has now 
gained fresh impetus owing to recent findings on its role in resolving inflammation. In 
addition, our knowledge concerning the role of PGE2 in the immunomodulatory effects of 
CAP is limited. Here, we have investigated the importance of PGE2 in the cholinergic 
regulation of inflammation by performing both in vivo and in vitro studies with mPGES-1 
gene deleted (mPGES-1 (-/-)) mice and human astroglial cells subjected to VNS and nicotine 
treatment respectively. We observed that inducible PGE2 production is crucial for VNS 
mediated splenic cholinergic synthesis and immunosuppressive effects during endotoxemia. 
These observations were applicable only to the splenic portion of the CAP, since VNS-
induced norepinephrine release from the splenic nerve was not dependent on PGE2, nor was 
the expression of b2-adrenergic receptors (AR) on effector T lymphocytes. Importantly, 
mPGES-1 pharmacological inhibition reversed nicotine immunomodulatory effects in LPS 
activated human peripheral blood mononuclear cells. Interestingly, while VNS did not affect 
the COX-1/2 expression, hypothalamic mPGES-1 was found to be elevated. In addition, 
COX-2 mediated PGE2 is involved in the cholinergic suppression of reactive astrogliosis and 
neuroinflammatory conditions. In conclusion, we propose that PGE2, which is known to drive 
febrile response and inflammatory pain during early stages of inflammation, can also have a 
regulatory role in the cholinergic immune regulation. 
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1 INTRODUCTION 
1.1 INFLAMMATION AND IMMUNITY  
The immune system plays a fundamental role in protecting us from life threatening pathogens 
and toxic substances. Immunity can be broadly classified as innate or adaptive. Innate 
immunity instantaneously provides the first line of protection against invading pathogens in 
organisms as small as fungi to highly complex vertebrates. It predominantly identifies 
pathogens through pathogen (PAMPs) and danger associated (DAMPs) molecular patterns 
expressed by innate immune cells. The key players involved in innate immunity include 
dendritic cells, macrophages, monocytes, neutrophils, eosinophils, basophils and mast cells. 
Interestingly, each one of them deploy a unique combination of defense strategies to destroy 
pathogens. In addition to phagocytosis, while neutrophils secrete large quantities of cytotoxic 
reactive oxygen species and proinflammatory cytokines like TNF and IL-12, macrophages 
and monocytes use nitric oxide to kill microbes. Intriguingly, phenotype (M1/M2) of 
macrophages engaged in an immune response is largely determined by the signals present 
during their differentiation and activation. Classically activated macrophages (M1) produce 
high levels of proinflammatory cytokines such as TNF a, IFN-g, IL-6 and IL-12 and possess 
potent antibacterial properties (1). Alternatively, macrophages (M2) generated in the presence 
of IL-4, IL-10, IL-13 and particularly glucocorticoids, usually secrete anti-inflammatory 
cytokines and thus play an immunoregulatory function.  Immediate hypersensitivity 
responses against allergens and immune response towards helminths and other parasites are 
mainly conducted by eosinophils, basophils and mast cells. Upon trigger, these innate 
immune cells release preformed toxic mediators from their cytoplasmic granules and secrete 
lipid mediators, thereby initiating tissue inflammation and edema (1).  
Apart from primarily initiating the immune response, innate immunity also activates and 
educates the adaptive immunity to carry out the secondary immune responses in an antigen 
specific manner. Importantly, antigen presenting cells such as macrophages and dendritic 
cells (DCs) are known to phagocytose pathogens, break them down into smaller peptide 
fragments that can be presented by major histocompatibility complex (MHC 1 and II) on their 
cell surface for antigen recognition by T cells. Depending on the MHC-antigen (Ag) complex 
presented and other costimulatory signals received, different subsets of T cells can be 
activated. For instance, CD8+ cytotoxic T cells predominantly kill intracellular pathogens and 
CD4+ helper T lymphocytes carry out cellular and humoral immune responses (B cell 
maturation) by engaging MHC I and II-Ag complexes respectively. CD4+ T helper population 
include different subsets such as Th1, Th2 and Th17 with varying effector functions. While 
Th1 and Th2 subpopulations are implicated in cell mediated and humoral/allergic immune 
responses, Th17 cells are responsible for the combat against extracellular bacteria, neutrophil 
recruitment to clear pathogens and destructive inflammatory response in autoimmunity. In 
contrast, a specified percentage of circulating helper T cells is established to participate in 
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down regulating immune responses by producing immunomodulatory cytokines such as IL-
10 and TGFb and are specifically called regulatory T cells (Treg).  
Inflammation, irrespective of the noxious stimuli, is coordinated by a surplus of cytokines 
and chemokines involved in recruiting immune cells to inflamed site, thereby inducing the 
cardinal signs of inflammation such as redness, swelling, pain, loss of function and fever. 
While the extent and intensity of inflammation mounted by an individual is determined by 
several factors, resolution of inflammation and restoration of homeostasis after the threat is 
eliminated is pivotal to keep onset of chronic inflammatory diseases at bay. Humoral (e.g. 
glucocorticoids) and cellular mechanisms (regulatory T-cells, M2 macrophages) are 
extensively studied for their role in regulating immune responses (2). Intriguingly, 
groundbreaking advances in the field of neuroimmunology have discovered specific neural 
mechanisms with immense therapeutic potential to control inflammation both in CNS and 
periphery (3).  
1.2 NERVOUS SYSTEM – AN OVERVIEW 
Human nervous system can be broadly classified as central (CNS) and peripheral nervous 
system (PNS). While CNS includes both brain and spinal cord, the PNS can be divided into 
autonomic (ANS) and somatic nervous system (SNS). Importantly, ANS is known to 
innervate cardiac muscle, smooth muscle and numerous glands and maintain homeostasis 
involuntarily. Many of the basic bodily functions are regulated by autonomic reflexes where 
sensory nerves convey important information from the periphery to respective control centers 
in CNS, incoming impulses are processed and a corresponding response is sent out through 
autonomic nerves to restore homeostasis. The efferent pathway of an autonomic reflex 
consists of two neurons. Preganglionic neurons emerging from CNS ends in an autonomic 
ganglion located outside CNS and connect with a post ganglionic neuron innervating the 
target tissue. Such reflexes support and sustain several vital processes namely blood pressure, 
heart rate, gastrointestinal peristalsis, body temperature etc.  
ANS can be further subdivided as either sympathetic (“fight or flight” response) or 
parasympathetic (“rest and eat” response). Both divisions are anatomically and functionally 
different with the ability to maintain effector functions in a tonic manner. Interestingly, 75% 
of the parasympathetic fibers belong to the vagus nerve which innervates several organs 
situated in the thorax and abdomen. The primary neurotransmitters released by ANS fibers 
are norepinephrine (NE) (adrenergic) and acetylcholine (ACh) (cholinergic) respectively. 
While all the preganglionic nerves of the ANS, post ganglionic nerves of parasympathetic 
system are cholinergic, postganglionic fibers of sympathetic system are mostly adrenergic. 
Sympathetic and parasympathetic post ganglionic nerves often exert opposing effects on the 
effector tissue. After exerting their effects, these neurotransmitters are rapidly cleared from 
their neuroeffector junctions by dedicated enzymatic degradation of ACh into choline and 
acetate or by reuptake of NE into the sympathetic nerve that released it.  These 
neurotransmitters can either inhibit or enhance the target function depending on the type of 
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receptor it activates on the cell surface. ACh can bind to two different types of receptors, 
nicotinic and muscarinic. Cell bodies of all post ganglionic nerves of ANS express nicotinic 
receptors and upon stimulation increase the intracellular Na+ and Ca2+ ion concentration 
resulting in excitation of the corresponding nerve fibers. On the other hand, muscarinic 
receptors are mostly found on the effector tissue and coupled to G proteins and second 
messengers that carry out intracellular outcomes. In case of NE, the adrenergic receptors can 
be divided as a and b. Each of these receptor groups can be further subdivided into different 
categories depending on their functions, intracellular pathways and location. (4) 
1.3 NEURAL REGULATING PATHWAYS 
1.3.1 Sickness syndrome and HPA axis 
Proinflammatory cytokines induced by systemic inflammation can reach the CNS either 
through circumventricular regions, activation of cytokine receptors or by induction of 
prostaglandins (PGs) across the blood brain barrier (4). CNS, in turn, orchestrates various 
symptoms of sickness behavior including fever, pain, reduced food intake and social activity. 
Brain endothelial and hypothalamic expression of PGE2 related enzymes such as COX-1/2 
and mPGES-1 are shown to play key roles in inducing sickness syndrome and hypothalamic-
pituitary-adrenal (HPA) axis, two main neural reflex responses to an immunological 
challenge (5). Increase in central PGE2 production at the cerebrovascular lining can diffuse 
into deep brain structures responsible for neural responses to systemic inflammation. For 
example, activation of EP3 (PGE2 receptor) bearing cytokine sensitive neurons in specific 
regions such as hypothalamus and medial preoptic area are shown to be involved in 
corticotrophin releasing hormone (CRH) upregulation and induction of febrile and pain 
responses (6). HPA axis, carried out by EP3 receptor activation on sympathetic neurons in 
hypothalamic paraventricular nucleus, sends out crucial negative feedback signal to immune 
system (7, 8). CRH expression in hypothalamus eventually leads to adrenocorticotrophic 
hormone (ACTH) release and subsequent upregulation of anti-inflammatory mediators, 
glucocorticoids, in the periphery. Glucocorticoids are well studied to suppress inflammation 
induced cytokine release and aid in restoring homeostasis in the host. 
1.3.2 Sympathetic regulation of immune responses 
Noradrenergic sympathetic nerves innervate primary and secondary lymphoid organs where 
the activated nerve endings can release NE in close proximity to many immune cell types 
such as macrophages, DCs, lymphocytes and others. Electron microscopic studies have 
clearly demonstrated the sympathetic nerve terminals in juxtaposition to T lymphocytes 
located in the splenic white pulp. b2 AR stimulation at physiological levels have been shown 
to mitigate acute and chronic inflammation partly by inhibiting important proinflammatory 
cytokines such as TNF and IL-1, limiting cellular immune response and enhancing Th2 
mediated antibody immunological action. The shift towards Th2 activity is achieved by 
increasing IL-4 and IL-10 cytokine release and at the same time, suppressing IFN-g and IL-12 
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levels. On the contrary, stimulation of a ARs increase TNF and IL-1 production and decrease 
IL-10 and IL-6, thereby fueling inflammation. Adding to the complexity, local NE 
concentration can have a differential impact on the target with high NE levels being generally 
inhibitory and low NE exhibiting excitatory effects. Thus, consequence of NE release on 
local immune population is largely determined by the type and density of adrenergic receptor 
(AR) expressed on the cell surface, concentration of NE in the milieu, G protein coupled to 
AR and activation status of the target (9). 
Intravenously injected LPS can activate sympathetic splanchnic and splenic nerve activity 
leading to an increase in plasma NE levels (10, 11). Interestingly, ANS has been associated 
with autonomic neural reflexes shown to dampen acute inflammation. For example, NE 
release in response to activation of the splenic nerve can suppress the production of 
proinflammatory cytokines through direct activation of its b2 receptors on activated 
macrophages (12). Furthermore, voluntary activation of sympathetic neural system in humans 
inhibited the inflammatory response mounted against LPS (13) and severing splanchnic nerve 
fibers increased LPS induced plasma TNFa levels (14). Increase in plasma TNFa levels 
following severed splanchnic nerve fibers and failure of vagotomy to abrogate splenic nerve 
activity in LPS treated animals led to the emergence of splanchnic anti-inflammatory  
pathway respectively (11). Such anti-inflammatory effects of sympathetic efferents are also 
demonstrated in zymosan induced air pouch model (15) and abdominal inflammation (16).  
1.3.3  Parasympathetic regulation of immune responses 
Induction of fever by even very low doses of LPS which do not produce measureable levels 
of cytokines in the periphery led to the discovery of afferent nerve signaling in immune to 
brain communication (17). The immune system has the ability to directly communicate with 
the CNS through cytokine (IL-1b) dependent activation of the afferent vagus nerves, which in 
turn, activate specific regions in the brainstem such as nucleus tractus solitarius (NTS) and 
dorsal motor nucleus (DMV) (18). The vagus nerve is the tenth cranial nerve which mainly 
originates from the cranium and innervates all principal visceral organs in a subconscious 
manner. The vagus nerve relays information to and from CNS and aids in maintaining 
behavioral and physiological homeostasis. A majority of the vagal afferents (nearly 80%) 
terminate in the NTS at the brainstem and known to control gastrointestinal, cardiovascular 
and respiratory systems (19). In addition, acute inflammatory models involving sub 
diaphragmatic vagotomy implicated the importance of afferent vagal signaling in mediating 
sickness syndrome and HPA activation in response to low doses of LPS or cytokines (20, 21). 
Interestingly, afferent vagus nerve fibers also seem to activate a central processing network 
leading to the activation of the efferent vagus nerve which effectively down regulates 
inflammation by inhibiting harmful cytokine production. Such a reflex mechanism solely 
dependent on the bidirectional neuro-immune communication became popularly known as 
the ‘inflammatory reflex’ (22). Functional studies on the inflammatory reflex identified ACh 
as the principal neurotransmitter in limiting inflammation following the efferent vagus nerve 
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stimulation. Hence, the efferent arm of the inflammatory reflex is called the ‘Cholinergic 
Anti-inflammatory Pathway’ (CAP). 
 
 
 
 
 
 
 
 
Figure 1. Immune to brain signaling. Our immune system can function as a sense organ to 
the CNS and convey key signals about the immunological status in multiple ways. 
Inflammatory cytokines can reach the CNS by 1. Active transport across blood brain barrier 
(BBB) 2. Passage through the circumventricular regions lacking BBB 3. Afferent vagal 
signaling and 4. Induction of PGE2 synthesis across the brain endothelial cells.  
Reprinted with permission from Journal of molecular medicine (6) 
1.4 CHOLINERGIC ANTI-INFLAMMATORY PATHWAY 
1.4.1 Overview  
Tracey and colleagues have performed extensive research on the anatomical details of the 
CAP and proposed a combined parasympathetic-sympathetic nerve model composed of 
vagus and splenic nerve respectively (3). Electrical stimulation of the cholinergic efferent 
vagus nerve ending in the celiac-mesenteric ganglion activates the adrenergic splenic nerve 
by a mechanism yet to be understood. The splenic nerve, in turn, releases NE in juxtaposition 
to immune cells in marginal zone, white and red pulp of the spleen, an important organ of 
CAP (23, 24). NE from the splenic nerve endings binds to its corresponding β2 AR expressed 
on effector memory T lymphocytes and induces ACh formation through action of choline 
acetyl transferase (ChAT) (25). Released ACh from T cells will then activate the α7nAChR 
on macrophages (26), thereby limiting cytokine production and inflammation as shown in 
Figure 2. In fact, CAP activation by VNS failed to limit inflammation and conversely, 
increased TNF production following endotoxin treatment in α7nAChR knock out mice (26). 
However, recent studies have also suggested the possibility of a direct action of NE on 
macrophages in bringing down inflammation (27). Hence, vagus nerve, splenic nerve and 
spleen become the main components of CAP to fine tune inflammation in a localized, 
specific and discrete manner (23, 28, 29). Apart from their profound effects on innate 
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immunity, CAP activation also modulated T cell independent B cell humoral response to heat 
activated Streptococcus pneumoniae where B cell migration and subsequent antibody 
production was obstructed (30). Furthermore, treatment with nicotine, a potent α7nAChR 
agonist, strongly reduced the Th1 and Th17 proliferation and associated cytokine levels and 
favored Th2 response which proved to be beneficial for alleviating disease severity in case of 
experimental autoimmune encephalomyelitis (31)  
1.4.2 Intracellular events of α7nACh receptor signaling 
Acetylcholine receptors are mainly classified as nicotinic and muscarinic receptors associated 
with different functions. M1 muscarinic receptors are mainly involved in the complex brain 
signaling of CAP (32). However, the peripheral effects of CAP are primarily carried out by 
the nicotinic receptors on activated macrophages. They are either homo- or hetero-pentameric 
ligand gated ion channels composed of 17 different subunits (α 1-10, β1-4, γ, δ, ε). Special 
attention is given to the α7nACh receptors that are detrimental to the integrity of CAP (33).  
Neuronal α7nACh receptors are usually homo-pentameric in nature and act as calcium 
channels involved in the regulation of neurotransmitter release in presynaptic nerve terminals 
and excitation of postsynaptic nerves. Apart from neurons, glial cells also express α7nACh 
receptors whose activation by ACh or nicotine can mediate neuroprotective effects during 
inflammation (34, 35). The intracellular mechanisms following activation of α7nACh 
receptors are well characterized in CNS (36). While the neuronal α7nACh receptors are 
associated with neuronal plasticity and survival (37), in contrast, their peripheral counterparts 
are involved in controlling inflammation and thus linked to a different intracellular pathway. 
Anti-inflammatory effects of α7nAChR are attributed to NF-kB inhibition and activation of 
JAK2/STAT3 signaling (38, 39). α7nACh receptor activation inhibits NF-κB migration to the 
nucleus by increasing IκB expression in human endothelial cells whereas the same outcome 
is achieved by inhibiting IκB phosphorylation and subsequent degradation in human 
monocytes (40, 41). Thus, different mechanisms are proposed depending on the cell type. On 
the other hand, α7 activation can also enhance the active STAT3 concentration intracellularly, 
which can either directly bind to NFκB and block its interaction with the DNA (42) or induce 
suppressor of cytokine signaling 3 (SOCS 3) expression (43). Altogether, the convergence of 
different molecular mechanisms in limiting cytokine release and possibility of other signaling 
pathways triggered by α7 ligation needs to be addressed in detail. 
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Figure 2. The Cholinergic Anti-inflammatory Pathway. Action potentials along the 
efferent vagus nerve induce NE release from splenic nerve endings. β2 AR activation results 
in increased acetylcholine production by effector memory cells (CD44hi CD62L lo) which in 
turn mediates immunosuppressive effects on splenic macrophages via α7nAChRs. 
Reprinted with permission from BioMed research international(44) 
1.4.3 Central projections of the vagus nerve  
Afferent vagal nerve fibers mainly project bilaterally to NTS in the medulla oblongata from 
where it directly enters parabrachial nuclei, the cerebellum, the raphe, the periaqueductal gray 
(PAG) and the locus coeruleus (LC) (45). Through the NTS, the vagus nerve also makes 
projections to the central cholinergic network composed of cortex, paraventricular nucleus, 
and lateral hypothalamic region among others. Activation of this network sends output 
signals through periaqueductal gray (midbrain), parabrachial nucleus (pons) and NTS, 
nucleus ambiguus and ventrolateral medulla (medullary nuclei) and conveyed to the 
periphery by the efferent vagus nerve (46).   
Stimulation of the vagus nerve results in NE production in the LC, primary source of NE in 
the brain. Interestingly, there are direct adrenergic nerve projections from LC to forebrain 
basal cholinergic system (47, 48) and NE release from LC can thus activate the brain 
cholinergic neurons via α1 receptors (49). Similar to the effects of CAP in the periphery, ACh 
has been shown to have neuroprotective effects on the activated microglia mediated by 
α7nAChR (34, 50) as illustrated in Figure 3. In parallel, selective M1 muscarinic receptor 
agonists have been elucidated to have positive effects on Alzheimer and schizophrenia (51). 
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In addition, projections from LC result in serotonin release at the dorsal raphe nucleus (DRN) 
that in turn can inhibit excitotoxicity by inhibiting glutamate release (52) and reducing NR2B 
subunit of N-methyl-D-aspartate receptor (53). Thus, CAP activation through electrical vagus 
nerve stimulation has the potential to also activate a cholinergic pathway in the brain and 
thereby control neuroinflammation. 
 
Figure 3. Potential neuroprotective effects of CAP. The afferent vagal pathway is 
represented by deep blue arrows and the efferent pathway by dark blue arrows. Majority of 
the vagal afferents converge at the NTS which upon activation induce NE release from the 
LC. NE subsequently increases the serotonin (5-hydoxytryptamine, 5-HT) levels at DRN. NE 
activates the central cholinergic network through α1AR resulting in ACh production and 
thereby limiting neuroinflammation through α7nAChR. On the other hand, 5-HT combats 
excitotoxicity by inhibiting glutamate release and NR2B expression. Apart from releasing 
ACh, central cholinergic network also sends anti-inflammatory signals through efferent vagus 
nerve fibers to the periphery.  
Reprinted with permission from Journal of cerebral blood flow and metabolism (54) 
1.4.4 Acetylcholine and inflammation  
Acetylcholine is synthesized by the enzymatic action of ChAT on the precursors choline and 
acetyl coenzyme A (acetyl-coA) respectively in the cytoplasm of preganglionic cholinergic 
nerve terminals. ACh is then transported into vesicles by specialized vesicular transporter 
system (VAChT)and upon stimulation, ACh is actively exocytosed into the synapses 
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resulting in the activation of postganglionic nerves. Interestingly, ACh thus synthesized is 
quickly hydrolyzed into choline and acetate by acetyl cholinesterase (AChE) and 
butyrylcholinesterase (BuChE) present in the synaptic cleft and circulation. For years, 
neurons were believed to be the only source of ACh, however, recent studies have challenged 
this paradigm by demonstrating the intrinsic ability of immune cells, glial cells, endothelial 
cells and many others to secrete ACh when challenged with endotoxin (55). In the CNS, 
microglia and astrocytes express ChAT activity and produce ACh in the resting as well as 
activated state(56). In CAP, splenic T lymphocytes are identified as the main source of ACh 
and function as a crucial mediator between the neural and immune system. Roses-Ballina 
(25), have discovered a subset of CD4+ T cells to actively produce ACh in a ChAT dependent 
manner upon β2 adrenergic receptor stimulation and thereby activate nicotinic or muscarinic 
receptors in an autocrine or paracrine fashion. Though CD8+ T cells, dendritic cells, 
macrophages, mast cells and granulocytes have all been shown to express ChAT, a major 
portion of ACh found in the circulation comes from CD4+ T cells (57). Furthermore, studies 
on human leukemia T cell lines displayed the up regulation of ChAT mRNA and protein 
expression owing to cell-cell adhesion with B lymphocytes, antigen presenting cells and 
endothelial cells (55). Cholinergic system in such non-neuronal cells appears to be regulated 
by protein kinase A (PKA), PKC and intracellular calcium concentration (58, 59). Unable to 
detect the presence of VAChT+ storage vesicles in human lymphocytes Fuji et al., suggested 
that, unlike the neurons, ACh could be synthesized and released instantaneously by 
lymphocytes (60). However, the possibility of unidentified storage vesicles cannot be 
excluded in light of mediatophore, a part of vacuolar type H+ ATPases (V-ATPase), 
discovered as an important mediator of ACh release in T cells (61). Thus, the mechanism of 
ACh release in lymphocytes still remains largely elusive.  
1.4.5 Cholinergic agonists and immune regulation 
Both T and B cells are known to express muscarinic (M1to M5) and nicotinic receptors (55).  
Studies on M1/ M5 mAChR knockout mice challenged with ovalbumin are shown to exhibit 
an impaired IgG1 production compared to the wild type (WT). In agreement with this finding, 
splenic mononuclear leukocytes from these KO mice secreted low levels of proinflammatory 
cytokines compared to WT upon stimulation (62). It is thus tempting to speculate the 
modulatory role of M1 and / or M5 mAChR in regulating the cytokine and antibody production 
by lymphocytes. In addition, M3 mAChR seems to play a detrimental role in CD4+ T cell 
development against parasites (63). However, in the case of CAP, peripheral muscarinic 
receptors seem to be a mute spectator with muscarinic antagonists unable to inhibit the anti-
inflammatory effects of VNS in mice (32). On the other hand, α7nAChRs function as a 
critical molecular link in CAP and ability of their agonists to limit inflammation as effectively 
as CAP has opened a pandora box. In recent past, several studies are conducted to decipher 
their therapeutic effects in chronic inflammatory diseases such as Alzheimer, rheumatoid 
arthritis, sepsis, stroke etc. (54, 64). For instance, use of nicotine and α7nAChR agonist AR-
R17779 ameliorated the severity of collagen-induced arthritis and decreased synovial 
 10 
inflammation in murine joints. AR-R17779 was more potent in delaying the onset of the 
disease and protecting the joints from destruction (65). Macrophages can be polarized to M1 
or M2 phenotype depending on their microenvironment. In general, M1 are believed to be 
proinflammatory and M2 to be anti-inflammatory in their function (66). While α7nAChR 
activation has been shown to protect M2 macrophages from ER stress induced apoptosis(67), 
it suppresses M1 macrophages infiltration in the adipose tissue, thereby reducing obesity 
induced inflammation and enhanced insulin sensitivity (68). However, little is known of the 
potential role of M1/M2 macrophage balance in central lymphatic organs, such as the spleen 
after activation of CAP. CAP can be activated by electrically stimulating vagus nerve and 
Tracey and his colleagues have invented a specialized device that can be surgically implanted 
on the left side of the neck in patients. Trials are currently underway in rheumatoid arthritis 
(RA) patients to test the clinical significance of VNS in treating chronic inflammation, and 
the initial results are promising (64). In addition, an alternative strategy could be the use of 
highly selective cholinergic α7 agonists for activation of CAP and regulation of peripheral 
inflammation.  
1.5 PROSTAGLANDIN E2  
1.5.1  Synthesis 
Prostaglandins are lipid mediators derived from arachidonic acid, mobilized by 
phospholipase A2 enzyme from membrane phospholipids, in response to physiological or 
pathological stimuli. Arachidonic acid is then converted to prostaglandin G2 (PGG2) and 
prostaglandin H2 (PGH2) by the enzymatic action of cyclooxygenases. PGH2 is then rapidly 
converted into members of the eicosanoid family such as PGE2, PGD2, PGI2, PGF2α or 
thromboxane (TXA2) by the terminal synthases as depicted in Figure 4.  
1.5.2 Cyclooxygenases and their complex role in inflammation 
Cyclooxygenases can be classified into COX-1 and 2 respectively. COX-1 is constitutively 
expressed whereas COX-2 is inducible and strongly associated with inflammation. However, 
reports have recorded exceptions implicating constitutive COX-2 and inducible COX-1 
expression in brain (6). Prostaglandins are produced by a wide range of cells and influence 
others in paracrine or autocrine fashion through their receptors (EP1-4, IP, TP, DP1-2, FP). A 
key question in earlier investigations was how peripheral inflammation could cause sickness 
response, characterized by fever, anorexia and hyperalgesia. Failure to induce fever in COX-2 
knock-out mice (69) and induction of fever in response to intracerebroventricular 
prostaglandin injection (70), shifted the focus towards cerebrovascular COX-2 induced PGE2 
as a key mediator in the neuro-immune crosstalk. This groundbreaking discovery along with 
studies confirming the pathological role of PGE2 at inflammatory sites (71) marked the 
beginning of use of nonsteroidal anti-inflammatory drugs (NSAIDS) and COX-2 inhibitors 
(NS-398) to treat inflammation and fever.  
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Figure 4. Prostanoid pathway. Arachidonic acid released from the plasma membrane by 
action of phospholipase A2 is readily converted to endoperoxide intermediates PGG2 and 
PGH2 by cyclooxygenases 1 and 2. Highly unstable intermediates are utilized by terminal 
synthases such as PGFS, PGDS, PGES, PGIS and TXAS to produce PGF2a, PGD2, PGE2, 
PGI2 and thromboxane A2 respectively. After its release, PGE2 exerts its effects by binding to 
either of its four seven transmembrane G protein coupled receptors (EP1-4). While activation 
of EP2/4 leads to increase in adenylyl cyclase activity and cAMP production, EP3 bound to 
inhibitory G protein executes opposite effects. In contrast, EP1 stimulation enhances 
intracellular calcium levels through the Gq-phospholipase C pathway.   
Reprinted with permission from Frontiers in endocrinology (72) 
 
NSAIDS include a heterogeneous group of COX-1/2 inhibitors shown extensively to control 
pain (anti-analgesic), inflammation (anti-inflammatory) and fever (anti-pyretic) in acute 
inflammatory conditions both in humans (73) and animals (74). However, effects of NSAIDS 
on chronic inflammation remains largely unknown. In animal RA models, effectiveness of 
NSAIDS were only restricted to reducing the joint pain and stiffness and did not hinder joint 
swelling and acute phase protein levels in blood (75). Interestingly, despite strong association 
with inflammation, COX inhibitors failed to stop the leukocyte infiltration in the synovial 
tissue and in contrast, induced the production of IL-6 and TNF a (76, 77). Importantly, 
studies have unraveled the unfavorable effects of chronic use of NSAIDS on cartilage erosion 
(78), skin (79), bone and tendon wound healing (80, 81). Use of NSAIDS are also linked to 
deadly side effects on gastrointestinal tract, kidney and cardiovascular system (82) resulting 
in 103,000 admissions and even worse, 3500 to 16500 deaths per year in the United States 
(83).  
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Owing to safety concerns, several NSAIDS such as rofecoxib, valdecoxib and others have 
been withdrawn from market and efforts are already underway to find alternative targets that 
can selectively deliver the therapeutic effects of NSAIDS without causing adverse effects on 
other physiological systems. Further studies in this line of research led to the discovery of the 
glutathione-dependent enzyme of the MAPEG family, microsomal prostaglandin E synthase 
(mPGES) as the terminal enzyme functionally coupled to COX-2 and responsible for the up-
regulation of central PGE2 in response to IL-1β in endothelial cells lining the cerebral vessels 
(84).  
1.5.3 Microsomal prostaglandin E synthase-1  
mPGES-1, an inducible isomerase of the terminal PGE synthase, is strongly associated with 
inflammation and pain among other synthases such as cytosolic PGES (cPGES) and mPGES-
2 that elicit physiological functions. In fact, cPGES (85) and mPGES-2(86) gene deletion did 
not result in any significant changes in the PGE2 levels in animals.. Though constitutively 
expressed in the urinary and reproductive systems, gastric mucosa, spleen, Kupffer cells and 
resident peritoneal macrophages, it is upregulated several fold in various organs and cell 
types such as brain, synovial fibroblasts etc. by noxious stimuli such as LPS, IL-1b etc (84, 
87). In addition, while cPGES is usually coupled to constitutive COX-1 activity, mPGES-1 is 
mostly believed to act downstream of COX-2, especially in inflammatory conditions (84, 88). 
In fact, massive outburst of PGE2 production seen 6 hours after the intraperitoneal LPS 
administration was completely abolished to basal levels in mPGES-1 knockout animals 
implicating its key role in inflammation induced PGE2 (89).  
Genetic deletion of mPGES-1 in mice has confirmed its participation in the pathogenesis of 
inflammatory diseases such as collagen induced arthritis (CIA), atherosclerosis, LPS induced 
pyresis, pain, experimental autoimmune encephalomyelitis, Alzheimer, stroke, multiple 
sclerosis (MS) and cancer (88). Interesingly, Trebino et al, have demonstrated reduced pain 
and edema formation in acute inflammatory models of mPGES-1 (-/-) mice(90). In chronic 
inflammatory models such as CIA, mPGES-1 depletion alleviated disease severity and joint 
damage compared to mPGES-1(+/+) (90). Furthermore, the reduced humoral response was 
attributed to the mPGES-1 deficiency in mesenchymal stromal cells (91). Clinical studies 
have shown both Alzheimer and MS patients to have increased COX-2 and mPGES-1 
expression in the brain compared to the controls. Neurons, astrocytes, microglia and 
endothelial cells are the primary source of mPGES-1 in Alzheimer (92). On the contrary, 
mPGES-1 expression was confined to microglia in MS (93).  
More research on understanding mPGES-1 structural properties and its role in inflammation, 
pain and cancer led to a quest searching for a selective mPGES-1 inhibitor to overcome the 
shortcomings and adverse effects of traditional NSAIDS and selective COX-2 inhibitors. So 
far, finding an ideal mPGES-1 inhibitor has been a herculean task owing to interspecies 
differences, ineffective potency and possible side effects such as impaired healing following 
myocardial infarction (88). Though deletion of mPGES-1 led to suppression of CIA, 
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contradictory observations were made in the case of collagen antibody induced arthritis 
(CAIA) with exacerbated disease severity owing to increased neutrophil recruitment to the 
inflamed joints (94). Moreover, parallel studies on mPGES-1 gene deleted mice in a chronic 
neuroinflammatory model displayed an impaired negative feedback mechanism on LPS-
induced cytokine synthesis, which was otherwise driven by mPGES-1 derived PGE2 and EP2 
activation in spinal microglia (95). A recent study in mice has shed light on the constitutive 
mPGES-1 expression in different regions of the brain expressed by different cell types such 
as pericytes, astroglial cells, leptomeninges and choroid plexus (96) As a consequence, while 
the pharmacological inhibition of mPGES-1 might be beneficial in the initial phase of 
inflammation, the possible deleterious effect on resolution cannot be ignored.  
1.5.4 Importance of PGE2 in resolving inflammation 
Induction, inflammation and resolution are three distinct stages of an acute inflammatory 
response. Similar to inflammation, resolution is indeed an active process shown to be driven 
by pro resolving mediators (97). Interestingly, COX-2 induced PGE2 is upregulated during 
the resolution phase of murine arthritis (98). In corroboration, blocking COX-2 activity and 
subsequent PGE2 synthesis during the inflammatory phase not only attenuated the magnitude 
of inflammatory response, but also delayed the resolution and tissue repair (99). These 
findings thus support use of NSAIDS during the induction phase, but strongly argue against 
their consumption at later stages of inflammation with potential detrimental effects on 
resolution and healing. Intriguingly, Chang et al suggest that mPGES-1, owing to its basal 
gene expression during resolution phase, might not contribute to COX-2/PGE2 mediated 
resolution (98). However, role of elevated mPGES-1 activity preceding resolution needs to be 
investigated.  
On the other hand, PGE2 have also shown to downregulate release of matrix 
metalloproteinases (MMP -1) by activated synovial fibroblasts, believed to cause tissue 
destruction in arthritic models (100). Non-selective COX inhibitors resulted in obvious  
increase in MMP-1 production. The anti-inflammatory effects mediated by PGE2 are 
attributed to ERK and NF-kB inhibition (101). Similar to nicotine, PGE2 blocks NF-kB 
activity either by inhibiting the nuclear translocation of p65 subunit or by increasing the IkB 
expression (102). In reality, several factors in the milieu could determine the effect of PGE2 
during inflammation. For example, in gastric epithelial cells, while PGE2 inhibited MMP-1 in 
presence of inflammatory cytokines, their absence reversed its effects (103). Thus, the role 
played by PGE2 during inflammation is solely dependent on time, context, concentration and 
cell type.  
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1.6 CHOLINERGIC IMMUNE REGULATION AND 
PROSTAGLANDIN E2  
Clinical significance of stimulating CAP is not only limited to treating acute inflammatory 
conditions, but can potentially be extended to limit chronic inflammation. Accumulating 
evidence showing its beneficial effects in arresting proinflammatory cytokine release and 
prolonging survival has promoted its use in treating patients suffering from rheumatoid 
arthritis (RA), hemorrhagic shock, sepsis, ischemia and other conditions (104). In light of 
recent findings demonstrating the ability of CD4+ChAT+ T cells to regulate blood pressure by 
stimulating vasorelaxant nitric oxide release(105), the therapeutic capability of VNS has 
reached new heights. In addition to inflammation, VNS is a well-tolerated treatment for 
epilepsy and depression and is not known to cause any immunodeficiency and adverse side 
effects (106). However, it is important to keep in mind that CAP is still not completely 
understood and existence of possible regulating systems cannot be excluded.  
Detailed mechanistic and functional studies on immunomodulatory effects of potent 
cholinergic agonists such as nicotine on immune cells have contributed immensely to our 
current understanding of neuro-immune regulation. Nicotine through its α7nAChR ligation 
blocked the expression of adhesion molecules including ICAM-1, B7.2 and CD40 and 
proinflammatory cytokines such as IL-12, IFNg and TNFa in IL-18 stimulated human 
monocytes and peripheral blood mononuclear cells (PBMC) respectively. Interestingly, these 
beneficial effects of nicotine were mediated by COX-2 dependent PGE2 production and 
corresponding EP2/4 receptors resulting in the elevation of intracellular cAMP secondary 
messenger concentration and PKA activity (107). Similar effects of nicotine on 
proinflammatory cytokines via COX 2-PGE2 pathway have also been studied in 
immunocompetent glial cells such as microglia (108). Intriguingly, PGE2 promoted non-small 
cell lung cancer (NSCLC) cell proliferation through α7nAChR expression following EP4 
mediated activation of c-Jun-N-terminal kinase (JNK), phosphatidylinositol 3-kinase (PI3-K) 
and PKA pathway(109). Convincing results on activated human leukemic T cell lines 
(MOLT-3) revealed the crucial role of PGE2 and its receptor EP4 in regulating lymphocytic 
cholinergic activity (110). Thus, prostaglandins seem to be important mediator in the 
cholinergic signaling and immune regulation. 
While the exact role of PGE2 during inflammation and resolution remains complex, its 
participation in mediating neuroregulatory events following systemic infection or 
inflammation is well known. Induction of PGE2 across the endothelial cells and parenchyma 
of the brain and subsequent onset of sickness syndrome and activation of HPA axis in 
response to systemic inflammation are extensively studied (5). In fact, administration of 
PGE2 in the CNS resulted in the neuronal stimulation of specific brain structures including 
NTS, a converging point for afferent vagus nerves (111). Interestingly, presence of IL-1b in 
the periphery activates the EP3, a subtype of PGE2 receptor, expressing cells at the vagal 
nuclei of CNS (18) and more studies with EP3 agonists and KO mice have confirmed EP3 to 
execute the functional effects of PGE2 in developing sickness behavior (112, 113). Cytokine 
  15 
induced action potentials along the afferent vagus nerve is pivotal for HPA activation (20). 
Thus, PGE2, apart from mediating immune responses, also serves as a crucial mediator in 
conveying important signals between the immune and CNS, ultimately resulting in the 
regulation of immune responses.  
Altogether, numerous studies have shown a functional relationship of PGE2 with cholinergic 
signaling, and interference with prostaglandin formation or metabolism may have important 
regulatory effects in the CAP. Moreover, the importance of PGE2 in initiating resolution may 
also involve secondary cholinergic immunosuppressive mechanisms and warrants further 
investigation. 
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2 AIMS 
2.2 GENERAL AIMS 
To comprehend the role of prostaglandin E2 as a neuro-immune mediator in the cholinergic 
anti-inflammatory pathway 
2.3 SPECIFIC AIMS 
2.3.1 To investigate the significance of mPGES-1 dependent PGE2 in the 
immunosuppressive effects of vagus nerve stimulation (VNS) in mice subjected to 
endotoxemia (in vivo) 
2.3.2 To dissect the effects of mPGES-1 gene deletion on the neuro-immune circuitry of 
CAP in endotoxemic mouse spleen (in vivo & in vitro) 
2.3.3 To explore the impact of VNS on the brain PGE2 related enzymes and substance P 
neuropeptide expression in endotoxemic mice (in vivo) 
2.3.4 To study the effects of nicotine on IL-1b activated human astrocytes and role of 
cyclooxygenase 2 dependent PGE2  in the cholinergic immune modulation. (in vitro) 
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3 METHODS  
3.1 STUDY I 
To investigate the significance of mPGES-1 dependent PGE2 in the immunosuppressive 
effects of VNS in mice subjected to endotoxemia (in vivo) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Animals: In bred DBA/1lacJ mice with Ptges gene deletion (mPGES-1 -/-) and 
congenic wild type controls (mPGES-1 +/+) were used in our experiments.  
Treatment: Isoflurane anesthetized mice underwent an incision at the neck and 
an electrode was placed under the carefully isolated vagus nerve. The electrode 
was in turn connected to AcqKnowledge software controlled electric stimulator. 
Lipopolysaccharide (2mg/kg) was injected intraperitoneally and five minutes 
later the vagus nerve was stimulated (5V, 1Hz for 5min). After VNS, the wound 
was stitched and animals were allowed to recover. SHAM animals were only 
subjected to LPS treatment and superficial neck incision.  
 
Extraction of tissues: Animals were euthanized 6 hours (cytokine/PG profiling) 
or 30 minutes (ACh measurement) after surgery. Serum from blood, spleen and 
brain were snap frozen at -80°C. 
Cytokine profiling 
 
MesoScale multiplex  
  
Acetylcholine measurement 
 
Choline/ACh assay 
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3.2 STUDY II 
To dissect the effects of mPGES-1 gene deletion on the neuro-immune circuitry of CAP in 
endotoxemic mouse spleen (in vivo & in vitro) 
 
 
 
 
Animals: In bred DBA/1lacJ mice with Ptges gene deletion (mPGES-1 -/-) and 
congenic wild type controls (mPGES-1 +/+) were used in our experiments.  
Surgery: LPS (2mg/kg) was injected 
intraperitoneally. Animals underwent 
either VNS or SHAM  
Extraction of tissues: Animals were 
euthanized 30 minutes after surgery 
and spleens were collected 
Primary splenocytes: Naïve mPGES-
1 (+/+) and (-/-) animals were 
euthanized and spleens were extracted  
Treatment: Cells were treated with 
NE or nicotine 30 min prior to LPS 
treatment or LPS alone for 3, 6 or 20 h 
In vivo In vitro 
Norepinephrine measurement 
Competitive ELISA 
 
 
Cytokine profiling 
MesoScale multiplex 
 
 
b2 adrenergic receptor 
 Flow Cytometry  
Choline acetyl transferase 
expression 
Indirect immunofluorescence 
 
Human PBMC: Fresh PBMC was isolated from buffy coats obtained from healthy 
donors and cultured in 96 well plates under sterile conditions  
Treatment: PBMCs were pretreated with mPGES-1 inhibitor and 30 minutes later 
stimulated with LPS or LPS+ nicotine simultaneously for 6, 14 and 20 hours  
Cytokine measurement 
 
Sandwich ELISA 
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3.3 STUDY III 
To explore the impact of VNS on the brain PGE2 related enzymes and substance P 
neuropeptide expression in endotoxemic mice (in vivo) 
 
 
 
 
 
 
 
 
 
 
 
 
Animals: C57BL/6 mice purchased from Nova-SCB, Sweden were used in our 
experiments.  
Surgery: LPS (2mg/kg) was injected 
intraperitoneally. Animals underwent 
either VNS or SHAM  
Extraction of tissues: Animals were 
euthanized 6h after surgery and brains 
were collected and snap frozen. Coronal 
sections of the tissue were prepared. 
c FOS, COX 1/2 mPGES-1 and SP 
 
In situ hybridization & 
Immunohistochemistry (ISH & IHC) 
mPGES-1 & GFAP 
Double immunofluorescence (IF) 
P ES-1  F P 
 
Double immunofluorescence 
 (IF) 
Treatment: Intrathecal or 
intraperitoneal injection of COX 
inhibitor SC 560 (10 or 100 µg) 30 
minutes prior to LPS (2mg/kg) injection 
Extraction of tissues: Animals were 
euthanized 2h or 6h after surgery and 
brains were collected and homogenized 
 
 
Cytokine profiling 
 
MesoScale multiplex 
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3.4 STUDY IV 
To study the effects of nicotine on IL-1b activated human astrocytes and role of 
cyclooxygenase 2 dependent PGE2 in the cholinergic immune modulation (in vitro) 
 
 
 
 
 
 
 
Human astrocytes: Primary human astrocytes were purchased ScienCell research 
laboratories and cultured in poly-L-lysine coated flasks as per manufacturer’s protocol 
under sterile conditions  
Treatment: Serum starved cells were 
stimulated with either IL-1b (10ng/ml) 
alone or in combination with nicotine for 
6, 20 and 48 hours.  
Treatment: Cells were treated with COX 
2 inhibitor NS-398 for 30 minutes and 
stimulated with IL-1b (10ng/ml) alone or 
in combination with nicotine for 20 hours.  
Cytokine profiling 
Sandwich ELISA / 
MesoScale multiplex 
GFAP & a7nAChR 
 
IHC & IF 
PGE2  
 
Enzyme Immunoassay 
AChE & BuChE 
Sandwich ELISA 
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3.5 METHODOLOGICAL CONSIDERATIONS 
3.5.1 Extraction of tissue samples 
Frozen or fresh tissue samples were homogenized using either polytron PT 10-35 GT or 
dounce homogenizer on ice. The protease and cyclooxygenase activity in the homogenates 
was inhibited using Sigma protease inhibitor tablet and indomethacin respectively. 
Homogenates were transferred to eppendorf tubes and centrifuged at 5000 rpm for 10 min. 
Supernatants were frozen at -80°C for further analysis for cytokine or PG profiling. This 
method of sample preparation is well established and used routinely in our experiments. 
3.5.2 Measurement of cytokines 
Sandwich Enzyme Linked Immuno Sorbent Assay (ELISA) 
We measured the mouse TNFa (Study II) and human TNFa, IL-6 and IL-8 levels in cell 
culture supernatants (Study IV) using sandwich ELISA. The detection range for mouse 
TNFa, human TNFa, IL-6 and IL-8 were 31.20 – 2000, 15.60 – 1000, 9.38 - 600 and 31.20 – 
2000 pg/mL respectively. Briefly, microtitre plates were first coated with primary antibodies 
for the respective cytokine overnight and incubated with the samples for 2 hours at room 
temperature. Following that, biotinylated secondary antibodies were added to the wells and 
later conjugated to streptavidin-horse radish peroxidase (HRP) conjugate. Finally, substrate 
solution containing hydrogen peroxide and tetramethylbenzidine (1:1 ratio) was added to 
individual wells and the color change was measured at 450nm and 562nm was used as the 
reference wavelength. The standard curve was made using a 4-parameter logistic fit and the 
concentration of each sample was calculated accordingly. The DuoSet ELISA method offers 
good sensitivity and specificity. Both fresh and frozen samples can be directly used. The 
method has no cross reactivity and multiple samples can be assayed in the same plate.  
MesoScale multiplex assay 
We used mouse (Study I, II and III) and human (Study IV) 10-plex assay for cytokine 
profiling of culture supernatants and tissue homogenates. This is an ultrasensitive multiplex 
kit where each well in the MSD 96-well plate contained 10 carbon electrodes. Each electrode 
was pre-coated with antibodies against a specific cytokine. Briefly, the wells were first 
blocked with assay diluent (25 µl), sealed and incubated for 30 min and later incubated with 
the samples overnight at 4°C with shaking. At the end of the incubation, the detection 
antibody was added, sealed and incubated for 2h at room temperature. Later, 150 µl of the 
MSD Read Buffer was added to each well. The MSD plate was read using the MSD Sector 
Imager 2400 plate reader. The raw data was measured as electrochemiluminescence signal 
(light) detected by photo detectors and analyzed using the Discovery Workbench 3.0 software 
(MSD). A 4-parameter logistic fit curve was generated for each analyte using the standards 
and the concentration of each sample was estimated. The MSD assay has a better sensitivity 
than cytometric bead array technique. The assay requires small sample volume, less hands-on 
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time, no prior expertise and offers a wide detection range for a cytokine of interest. However, 
use of this technique demands a dedicated electrochemiluminescence reader.  
3.5.3 Choline/Acetylcholine assay  
We homogenized the spleen in the assay buffer and used it immediately to measure the 
choline and acetylcholine levels by using a simple and sensitive colorimetric method (Study 
I). Free choline is converted to betaine which reacts with the choline probe to develop color 
at 570nm. The same technique can be used to quantify the total choline content by adding 
acetylcholinesterase to the reaction mix. Thus, ACh concentration in the supernatant can be 
calculated by using the formula (total choline – free choline). The assay can detect ACh 
levels ranging from 10pmol to 5nmol. The method is quick, easy to perform and does not 
require any special expertise. On the other hand, the method is unsuitable for analyzing 
already frozen samples. In Study I, we used this assay only to measure ACh levels in freshly 
isolated spleens. Our goal to quantify ACh levels in NE treated splenocyte culture 
supernatants (Study II) turned out to be unsuccessful due to the poor sensitivity of the 
Choline/Acetylcholine kit and lack of time and expertise in optimizing conditions for ACh 
measurement by LC-MS/MS.  
3.5.4 Norepinephrine assay 
We quantified the NE levels in the homogenized spleens using competitive ELISA (Study II) 
technique. In short, NE was derived enzymatically and transferred to precoated noradrenaline 
microtiter plates. The analyte competes for specific number of antibody binding sites and 
later quantified using anti-rabbit IgG peroxidase conjugate-TMB detection method. The 
absorbance was read at 450 nm and 630 nm was used as reference wavelength. The 
sensitivity of the kit is 0.1ng/ml * correction factor and cross reactivity is less than 0.48 %. 
The detection range is 1.3 – 32000 pg/ml. The disadvantage of this technique is 
homogenizing the samples in a buffer containing EDTA (1mM) and sodium metabisulfite (4 
mM) for avoiding NE degradation makes it unsuitable to be used for measuring other 
analytes. Similar to ACh, NE can also be effectively measured using LC-MS/MS. 
3.5.5 Flow cytometry 
b2 adrenergic receptor expression on CD4+ T lymphocytes was measured using flow 
cytometry (Study II). Single cell suspensions of fresh spleens were prepared and CD4+ cells 
were positively selected using magnetic microbead separation. CD4 enriched cell population 
was incubated with the following panel of anti-mouse antibodies: PE ADBR2 (bs-0947R-PE, 
Bioss Antibodies, USA), PE/Cy7 CD 62L (560516, BD Pharmingen, Europe), BV 510 CD 4 
(100553, BioLegend, USA), APC Cy7 CD3 (100222, BioLegend, USA) and APC CD44 
(103012, BioLegend, USA). Viability of cells was measures by using LIVE/DEAD™ 
Fixable Green Dead Cell Stain Kit. Stained cells were fixed (4% paraformaldehyde) and 
samples were acquired the following day using a BD FACSVerse instrument evaluating a 
minimum of 60000 live single cells. Calculation of compensation matrix and analyzation of 
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data was performed using FlowJo v.X software. Due to limited number of cells, the 
compensation was set by using single stained beads and gates were corrected using 
appropriate FMOs. b2 adrenergic receptor expression was reported as % parent population 
and mean fluorescence intensity. Flow cytometry technique helps to analyze the expression 
of the desired protein among specific cell populations and provides a platform to study 
multiple protein targets. At the same time, the limited choice of antibodies and 
fluorochromes, non-specific binding and compensation might be considered as limitations.   
3.5.6 In situ hybridization 
This method was used to study c-Fos, COX-2 and substance P mRNA levels in coronal 
mouse brain sections (Study III). Hybridization was carried out using complementary 
oligoprobes labeled with [α-33P] dATP. Briefly, air dried sections were incubated with 
hybridization cocktail in a humidified chamber for 16-18 h at 42°C. After hybridization, the 
sections were washed and dehydrated using alcohol. The sections were then developed using 
Kodak D19, fixed in Kodak Unifix and mounted. In order to check probe specificity, adjacent 
sections were incubated with an excess (100x) of unlabeled probe. This method enables us to 
localize and measure mRNA expression of a specific target in specific regions of the mouse 
brain. It preserves the integrity of the cells in the tissue section. Varying sensitivity of the 
available probes and long time required for developing signal are the caveats. 
3.5.7 Immunohistochemistry 
This technique was used to analyze the protein expression of COX-1/2, mPGES-1 in mouse 
brain sections (Study III) and a7nACh receptor on activated human astrocytes (Study IV). 
Briefly, the protein of interest is detected on paraformaldehyde fixed mouse brain sections by 
using polyclonal or monoclonal primary antibodies raised in rabbit, goat or rat. Later, the 
unbound antibodies are washed and the bound primary antibodies are recognized by using 
biotinylated secondary antibodies raised against them. Following that, an avidin-biotin- 
peroxidase complex is used to amplify the signal. The detection mixture contains hydrogen 
peroxide and chromagen 3,3’-diaminobenzidine tetrahydrochloride (DAB) which later 
develops into brown color (positive signal). The unspecific binding was averted by blocking 
the endogenous peroxidase, avidin and biotin activity. The specificity of the primary and 
secondary antibodies was confirmed using appropriate isotype control and by excluding 
primary antibodies accordingly. The main advantages of this method are able to detect the 
protein of interest at the cellular level, signal amplification, long lasting signal compared to 
fluorescent dyes and greatly helps to analyze region specific differences. The disadvantages 
are possibility of getting a high background, requires optimization and difficult to study co-
localization. We minimized background by incorporating blocking steps for avidin, biotin 
and endogenous hydrogen peroxidase and used immunofluorescence to study co-localization. 
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3.5.8 Indirect immunofluorescence 
This method was used to detect the protein expression of choline acetyltransferase (ChAT) 
enzyme in mouse splenocytes (Study II), to co-localize mPGES-1 and GFAP expression in 
mouse brain sections (Study III) and GFAP and a7nAChR expression in activated human 
astrocytes (Study IV). The detection was either performed using primary antibodies directly 
conjugated to fluorophores or using biotinylated secondary antibody -streptavidin detection 
system. This technique offers ease of multiplexing, fewer steps and wide dynamic range 
compared to immunohistochemistry. Lower sensitivity and photobleaching are the main 
disadvantages.  
3.5.9 Enzyme Immunoassay 
This method was used to quantify the PGE2 content in culture supernatants (Study IV). The 
assay employs a forward sequential competitive binding technique where the analyte 
competes with HRP-conjugated PGE2 for specific number of binding sites on monoclonal 
antibody bound to the plate. The HRP activity is then measured using an appropriate 
substrate at 450nm. The pros are simple to perform, sensitivity is 41.4 pg/ml, broad detection 
range is 39 - 2500 pg/ml and less cross reactivity. Lack of multiplexing for other PGs in the 
same sample, lesser sensitivity, accuracy and specificity compared to LC-MS/MS are the 
cons of enzyme immunoassay. 
3.6 VAGUS NERVE STIMULATION 
In our experiments, we carefully isolated the left cervical vagus nerve and electrically 
stimulated it for 5 mins. The stimulation parameters (1Hz for 2ms at 5V) used are in 
accordance with the previous studies demonstrating cytokine inhibition (29). We neither 
studied the electrical current dose response nor stimulation time dependent effects on 
inflammation. In contrast to earlier studies on VNS effects in acute inflammatory models, we 
chose to collect samples after 6 hours, a time point when both cytokine and prostaglandins 
are known to be elevated (5, 29). We induced endotoxemia in mice at a lower dose of LPS 
(2mg/kg) for the following reasons. It was ethically unacceptable to use the original lethal 
dose of 15mg/kg and keep the animals for 6 hours and on the other hand, a high dose of LPS 
could potentially mask effects of prostaglandin and thus make it unsuitable for our studies. 
We have shown that this modified LPS dose is adequate to cause sufficient proinflammatory 
cytokine release and most importantly, immunosuppressive effects of VNS were still evident 
after 6 hours of treatment in our endotoxemic model (114). 
3.7 mPGES-1 GENE DELETION AND PHARMACOLOGICAL 
INHIBITION 
To understand the role of mPGES-1 in VNS mediated CAP, we used in bred DBA/1lacJ mice 
with Ptges gene deletion (mPGES-1 -/-) and congenic wild type as controls (mPGES-1 +/+) 
(Study I and II). Mouse Ptges gene is composed of 40.4 kilobases inclusive of three exons 
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located on chromosome 2 and shares 84% homology with its human counterpart. 
Homozygous littermates were obtained by crossing heterozygous (mPGES-1 +/-) males and 
females and genotypes were later confirmed by PCR. Mice with mPGES-1 gene deletion are 
viable, reproduce and develop normally in comparison to mPGES-1(+/+) (90). No differences 
were spotted in general behavior, appearance, weight and hematological factors. In addition, 
deletion of mPGES-1 gene had no effect on the expression of COX-2 and other prostaglandin 
synthesizing enzymes (90, 115), blood pressure and thrombogenesis (116). Though no 
differences were detected among the constitutive prostanoid levels, LPS treatment resulted in 
significant suppression of PGE2 levels and shunting was seen towards thromboxane B2 
(TxB2) and PGD2 metabolite in mPGES-1(-/-) compared to mPGES-1(+/+) macrophages. 
Interestingly, mPGES-1 gene depletion did not affect the total fatty acid composition in 
activated cells and brain tissue but induced some changes in inflamed treated spleen(117).  
Pharmacological inhibition of mPGES-1 activity was carried out by using Compound III, a 
benzoimidazole derivative (Study II). Compound III inhibits both human and rat 
recombinant mPGES-1 and displays high selectivity towards mPGES-1 among other 
prostanoid synthases. Under stimulated conditions, mPGES-1 inhibition significantly 
decreased PGE2 and increased prostacyclin metabolite 6-keto-PGF1a in vitro. Intriguingly, in 
the inflammatory air pouch model, while both mPGES-1 gene deletion and inhibition failed 
to affect exudate volume, they elicited opposing effects on the cellular infiltration. Moreover, 
while the excess PGH2 resulting from mPGES-1 deletion caused shunting to TXB pathway, 
inhibition of its enzymatic activity did not affect other prostanoids in vivo (118). 
3.8 STATISTICAL ANALYSES 
All the statistical tests were done using Graph Pad Prism 6.0 software. 
Study I 
Data are represented as mean±standard error mean (SEM) for all samples and analyzed using 
one-way analysis of variance (ANOVA) followed by Bonferroni’s post hoc test for multiple 
comparisons.  Statistical significance was set at P values less than 0.05. 
Study II 
All samples were run in duplicates and data are represented as mean±SEM. Statistical 
analyses were performed using one-way ANOVA (Bonferroni’s post hoc test) or Student’s 
T–test. P values ≤ 0.05 were considered as statistically significant.  
Study III 
All values are represented as mean ±SEM and analyzed using Student’s T-test or one-way 
ANOVA (Bonferroni’s post hoc test). Differences between treatment groups were considered 
to be significant for P values less than 0.05. 
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Study IV 
Samples were run in duplicates and reported as mean±SEM. Data was analyzed using one-
way ANOVA (Bonferroni’s post hoc test) and P values ≤ 0.05 were considered as statistically 
significant.  
3.9 ETHICAL CONSIDERATIONS 
Animals were fed and maintained under temperature controlled, pathogen free conditions as 
per the guidelines of care and use of animals. Mice were allowed to acclimatize to our facility 
for a minimum of 1 week prior to the onset of experiments at constant room temperature and 
a 12 hr light/dark cycle.  All procedures were performed and approved by the Regional Ethics 
Committee at Karolinska Institutet, Sweden. 
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4 RESULTS AND DISCUSSION 
Study I. 
mPGES-1 dependent PGE2 is crucial for the complete functioning of the 
cholinergic anti-inflammatory pathway in endotoxemia 
PGE2 is known to play a central role in the bidirectional communication between central 
nervous and immune system, especially during peripheral inflammation. Onset of sickness 
syndrome and HPA axis, induction of pain and activation of EP3 (PGE2 receptor) bearing 
cells in the vagal nuclei in response to systemic inflammation (6) has clearly demonstrated 
the indispensable role played by PGE2 in neuro-immune interactions and possible 
involvement in immunoregulatory mechanisms. In fact, administration of PGE2 in the CNS 
resulted in the neuronal stimulation of specific brain structures including NTS, a converging 
point for afferent vagus nerves (119). This prompted us to question the role of PGE2 in 
association with immunosuppressive effects of VNS. Since inflammation induced PGE2 
synthesis is mainly attributed to the terminal enzyme mPGES-1 (120), we chose to study the 
outcome of VNS on LPS induced cytokine production in mPGES-1 (+/+) and mPGES-1 (-/-) 
mice in vivo.  
In 2000, Borovikova and colleagues (121) clearly demonstrated the attenuating effects of 
electrical stimulation of vagus nerve on the TNFa synthesis in endotoxemic adult rats. In 
accordance with their results, we observed that VNS resulted in the strong 
immunosuppression in endotoxemic mPGES-1(+/+) mice compared to SHAM (LPS+ neck 
surgery only). VNS treatment significantly inhibited TNFa, IL-1b, IFNg and IL-12 in the 
serum. Importantly, VNS limited TNFa production in the spleen, a major target organ in LPS 
induced inflammation and CAP. Intriguingly, in the case of mPGES-1 (-/-), VNS failed to 
hamper the production of proinflammatory cytokines both in the serum (Figure 5) and 
spleen. Importantly, in line with Uematsu et al., (89) deletion of mPGES-1 gene did not 
impede the upregulation of any of the LPS induced cytokines both in the serum and spleen. 
This helped us to conclude that the failure of VNS to suppress inflammation in mPGES-1(-/-) 
mice is solely due to absence of mPGES-1 dependent PGE2 production and cannot be 
attributed to a general cytokine release impairment related to the genotype.  
Next, the PGE2 production in response to VNS/SHAM treatment was investigated in the 
spleen and brain respectively. Interestingly, VNS did not increase PGE2 levels in the 
endotoxemic mouse spleen in mPGES-1(+/+). On the other hand, as expected, the mPGES-1 
gene deletion in mPGES-1(-/-) mice abolished nearly 80 % of the PGE2 release in response to 
LPS with no major differences between SHAM and VNS treatment. In parallel, apart from 
similar observations in homogenized mouse brains with regard to mPGES-1 dependent PGE2 
synthesis, we could detect a significant suppression of PGD2 in both SHAM and VNS of 
mPGES-1 (-/-) mice.  
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Local PGE2 has been shown to increase ChAT and ACh production through EP4 activation in 
phytohaemagglutinin (PHA) treated human leukemic cell line (MOLT-3) (110). In 
corroboration with these findings, VNS induced ACh release was evident in mPGES-1 (+/+) 
spleen, however such an effect was abrogated in mPGES-1(-/-) mice as shown in Figure 6. 
Thus, we could conclude that, in response to VNS, mPGES-1 (-/-) mice displayed both a 
defective immune suppression and lack of the earlier observed peak in VNS-induced 
acetylcholine production. These findings thus, not only implicated the importance of PGE2 
for the optimal functioning of CAP but also raised several research questions that were 
further addressed in Study II and III.  
It is important to note that activation of CAP by VNS is not only restricted to electrical 
stimulation of efferent vagus nerve but also sends action potentials along afferent nerve fibers 
(122). Moreover, while the series of neuro-immune events orchestrated by efferent vagus 
activation is well categorized (123), the potential effects of afferent VN on the CNS remains 
elusive. PG profiling on brain and spleen homogenates was instrumental in confirming the 
inhibition of PGE2 synthesis in mPGES-1(-/-) mice, however by using this method potential 
region-specific differences related to VNS in mPGES-1(+/+) brain could be lost. In order to 
understand the impact of mPGES-1 depletion on CAP in detail, we decided to study the 
already elucidated CAP related events in mPGES-1(-/-) mouse spleen (Study II) and examine 
the effects of VNS on PGE2 related enzymes in specific regions of the endotoxemic mouse 
brain (Study III).  
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Figure 5. Cytokine production in mPGES-1 (+/+) and (-/-) mouse serum after SHAM 
and VNS treatment.  
 
 
 
 
 
  
 
All animals have received LPS (2mg/kg) injection. VNS induced suppression of TNFa was 
abolished following mPGES-1 gene deletion. All values are represented as mean ± SEM and 
*p<0.05 (One-way ANOVA) denotes statistical differences between VNS and corresponding 
SHAM mice (n=6-7 per group). 
 
Figure 6. ACh release in mPGES-1 (+/+) and (-/-) spleen extracts after SHAM and VNS 
treatment. 
 
VNS increased ACh content compared to SHAM in mPGES-1 (+/+) spleen. In contrast, 
mPGES-1 deficiency impaired the ACh release in response to VNS. Data are expressed as 
ng/mg of spleen. **p<0.01 (One-way ANOVA) compared to SHAM (+/+); ## compared to 
VNS (+/+) (n=6 per group). 
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Study II  
mPGES-1 gene deletion impairs the neuro-immune circuitry of CAP in the 
endotoxemic mouse spleen 
Detailed mechanistic studies on CAP have shown activation of the splenic nerve by VNS to 
release sympathetic neurotransmitter NE in juxtaposition to b2 adrenergic receptor (AR) 
expressing CD44hi CD62Llo effector memory T cells residing in the white pulp of spleen (25). 
Based on our current understanding of CAP, defective ACh synthesis in response to VNS 
treatment following mPGES-1 genetic deletion, in Study 1, could be an outcome of (i) 
insufficient splenic nerve activity, (ii) defective expression of b2 adrenergic receptors or (iii) 
setbacks in the cholinergic synthesis machinery.  
 In mice, intravenous LPS treatment has been shown to increase the sympathetic splenic 
nerve activity and such an effect is believed to be mainly mediated by the central PGE2 
synthesis (10). In our experiments, though the splenic nerve activation is directly linked to 
VNS, given the fact that mPGES-1 gene deletion significantly reduced brain PGE2 levels, we 
wanted to verify if it could affect the splenic NE release in response to VNS in mPGES-1(-/-) 
mice. On the contrary, VNS induced splenic NE release was intact despite the depletion of 
mPGES-1 dependent PGE2 expression as depicted in Figure 7. This result helped us to rule 
out the possible involvement of brain PGE2 in affecting splenic nerve activation associated 
with VNS and pointed out to the possibility of mPGES-1 gene deletion affecting other 
molecular events downstream of NE release in CAP.  
Recent studies on b2 AR (-/-) mice, proved the importance of the b2 adrenergic receptor in 
executing the immunoprotective effects of VNS (12). We examined the b2 adrenergic 
receptor expression on CD 44hi CD 62Llo effector memory cells among the spleen lymphocyte 
population following VNS treatment. In comparison to mPGES-1 (+/+), mPGES-1 gene 
deletion did not affect the naïve (CD44lo CD62Lhi), effector (CD44lo CD62Llo), central 
memory (CD44hi CD62Lhi) or effector memory (CD44hi CD62Llo) populations following 
VNS in LPS treated mouse spleen. Moreover, no significant differences were observed in b2 
adrenergic receptor expression between the VNS treated mPGES-1(+/+) and (-/-) effector 
memory cell populations. Thus, mPGES-1 depletion altered neither the proportion of effector 
memory population nor the expression b2 adrenergic receptors on their cell surface.  
LPS activation of splenocytes prepared from both mPGES-1 (+/+) and (-/-) mouse resulted in 
high concentrations of proinflammatory mediators such as TNFa, IL-6 and KC GRO in 
culture supernatants. Interestingly, treatment of activated mPGES-1 (+/+) splenocytes with 
NE mitigated the cytokine synthesis. However, such limiting effects of NE were strongly 
altered in case of TNFa and negated in IL-6 and KC GRO in the absence of mPGES-1 
expression. Unlike neurons, immune cells cannot store and release ACh instantly upon 
activation and instead produce it by the enzymatic action of choline acetyl transferase 
(ChAT) on choline (59). As shown earlier by Vijayaraghavan et al. (124), LPS activation 
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increased ChAT protein levels in mPGES-1 (+/+) splenocytes. On the contrary, though 
mPGES-1 (-/-) splenocytes expressed relatively similar ChAT expression under resting 
conditions, it failed to augment its protein levels upon LPS stimulation as shown in Figure 8. 
Intriguingly, mPGES-1 gene deletion completely abolished the mitigating effects of nicotine 
treatment in LPS activated splenocytes. Translational experiments involving pharmacological 
inhibition of mPGES-1 function in LPS stimulated human PBMC led to upregulation of 
TNFa synthesis. In line with mouse splenocyte data, nicotine’s immunomodulatory effects 
on activated human PBMC were negated by mPGES-1 inhibition. These findings 
complement the numerous studies that suggest involvement of PGE2 in the cholinergic 
limiting effects on destructive cytokine release (107, 108).  
We demonstrate here for the first time that central mPGES-1 dependent PGE2 synthesis is not 
crucial for VNS mediated splenic nerve activation and subsequent NE release. On the 
contrary, we observed a strong involvement of mPGES-1 dependent PGE2 in cholinergic 
synthesis and immune regulation of activated immune cells in the spleen. In conclusion, our 
data implicate the importance of mPGES-1 dependent PGE2 in cholinergic synthesis and 
regulation of immune responses following CAP activation in mouse spleen as depicted in 
Figure 9.  
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Figure 7. Splenic norepinephrine release in mPGES-1 (+/+) (WT) and (-/-) (KO) animals 
following VNS. 
 
 
 
 
 
 
 
 
Electrical stimulation of the VN increased splenic NE content by ~ 2-fold irrespective of the 
presence or absence of mPGES-1 expression. All values are represented as mean±SEM from 
4-5 individual animals per treatment (**p<0.01; SHAM versus VNS; One-way ANOVA) 
 
Figure 8. Choline acetyltransferase expression in LPS stimulated mPGES-1(+/+) and  
(-/-) splenocytes 
 
 
 
LPS 10ng/mL    -    -        +   + 
Unstimulated mPGES-1(+/+) and (-/-) splenocytes displayed similar levels of ChAT 
expression. LPS increased percentage of ChAT positive cells among mPGES-1(+/+) 
splenocytes (* p<0.05; LPS versus control within mPGES-1(+/+); Mann-Whitney Test). On 
the contrary, LPS failed to increase ChAT expression mPGES-1 depleted splenocytes 
(*p<0.05; mPGES-1(+/+) versus (-/-) within the LPS treatment group; Mann-Whitney Test). 
All values are represented as mean±SEM from two independent experiments. 
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Figure 9.  Schematic diagram of VNS mediated event in mPGES-1 (+/+) and (-/-) spleen 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In an endotoxemic spleen, VNS induces splenic nerve (SN) NE release adjacent to CD44hi 
CD62Llo T cells resulting in b2 AR stimulation and ACh synthesis. Subsequent α7 nAChR 
interaction on activated macrophages increases endogenous PGE2 and cAMP through EP2/4 
activation, thereby controlling inflammation. In our current study, we demonstrate that in 
mPGES-1 gene deleted mice, VNS induced sympathetic SN activation and b2AR expression 
on effector memory cells are intact. However, choline acetyltransferase (ChAT) dependent 
ACh release and inhibition of cytokines in response to nicotine (α7nAChR agonist) are 
impaired, thereby clearly demonstrating the role of mPGES-1 dependent PGE2 as a crucial 
mediator in the cholinergic processes related to VNS. 
Norepinephrine 
Proinflammatory  
cytokines  
Proinflammatory  
cytokines  
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Study III  
Treatment of endotoxemia by vagus nerve stimulation increases mPGES-1 
expression and limits substance P neuropeptide synthesis in mouse brain  
Data from Study I showed that immunosuppressive effects of VNS were highly compromised 
in endotoxemic mice lacking mPGES-1 expression and VNS had no effect on the PGE2 
protein levels of LPS inflamed spleen under the described experimental conditions. At the 
same time, upregulation of PGE2 synthesis across brain endothelial cells and parenchyma 
including vagal nuclei induced by systemic inflammation and its role as neuro-immune 
mediator in initiating sickness syndrome and HPA axis has been well studied (6, 125). In 
addition, stimulation of VN can increase brain cholinergic activity through afferent vagus 
activation (54) and limit COX-2 expression in specific brain regions (126). This raises an 
interesting research question of the potential effects of VNS on PG system in endotoxemic 
brain. Thus, we aimed to study the effects of VNS on the brain PGE2 related enzymes (COX- 
1/2 and mPGES-1) and substance P expression in mouse brain during endotoxemia using in 
situ hybridization and immunohistochemistry.  
We identified specific brain regions that were activated by acute VNS by measuring the 
expression of the neuronal activation marker, c-Fos. We observed strong c-Fos activity in 
hippocampus, hypothalamus, cingulate cortex, periaqueductal grey (PAG), and dorsal raphe 
nucleus (DRN) which are proven to be associated with memory, stress, mood, pain and 
serotonergic neurotransmission (127). Interestingly, acute VNS resulted in significant 
enhancement of LPS induced c-Fos expression in hippocampus and hypothalamus. On the 
contrary, in agreement with Cunningham et al., VNS did not affect LPS induced c-Fos levels 
in cingulate cortex and DRN. However, chronic VNS has been reported to activate ∆Fos, a c-
Fos metabolite, in both regions mentioned above (127). VNS also strongly inhibited the LPS 
induced brain substance P expression in all regions studied except the DRN, which explain 
the anti-nociceptive effects of VNS in migraine(128).   
Immediate release of PGE2 in response to injury or infection is generally fueled by COX-1 
enzymatic action followed by COX-2 during the later stages of an immune response (129). In 
contrast, brain inflammation is mostly associated with COX-2 activity (130). In support of 
this, we observed a significant increase in COX-2 protein levels in hypothalamus, PAG and 
DRN following LPS treatment. In contradiction to the recent reports on VNS resulting in 
decrease of COX-2 mRNA in the cortex (126), we did not detect any significant differences 
in LPS treated brain COX-1 and 2 expression following VNS. It is noteworthy to mention 
that a time dependent analysis is required to better understand the VNS effects on COX 
enzymes.  
Contradictory findings exist concerning the constitutive expression of mPGES-1 in the brain. 
Engblom et al have reported basal mPGES-1 expression to be rare and restricted to specific 
regions in the rat brain parenchyma (125). However, in support of Eskilsson and colleagues 
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(96), we detected constitutive mPGES-1 expression in all regions examined. In addition, LPS 
treatment alone did not alter the constitutive expression of mPGES-1 in the mouse brain in 
any way. These differences, however, could be species dependent and needs further 
investigation. Intriguingly, in connection with our earlier results (Study I) suggesting 
mPGES-1 dependent PGE2 involvement in CAP, VNS increased mPGES-1 protein level in 
the hypothalamus (Figure 10) and displayed a tendency to increase mPGES-1 expression in 
other regions such as cingulate cortex, PAG and DRN. Interestingly, in line with previous 
studies (96) reporting astrocytic mPGES-1 expression, we observed mPGES-1 co-
localization with GFAP positive astrocytes in the hypothalamus, hippocampus, cortex and 
along blood vessels in VNS treated inflamed mouse brain.  
In another set of experiments carried out to study the impact of PG inhibition on 
neuroinflammation, LPS treatment for 2 hours increased the release of IL-6, IL-1b and 
CXCL1 in both brain and spleen homogenates. Intriguingly, intrathecal COX inhibition 
further increased the above-mentioned cytokines to significant levels in the brain. On the 
contrary, intraperitoneal treatment of the same COX inhibitor at a dose 10 times higher than 
i.t did not change the LPS induced brain cytokine production. Interestingly, both systemic 
and central COX inhibition had no effect on the LPS induced cytokines in the spleen.  
Thus, our data illustrates that electric stimulation of VN is associated with activation of 
specific regions of mouse brain. Increase in hypothalamic mPGES-1 expression in response 
to VNS further reiterates the interdependence between cholinergic and PGE2 systems in 
immune regulation. Finally, our COX inhibition results hint at the possible involvement of 
COX dependent PGs in brain cytokine production following peripheral inflammation. 
Figure 10. Hypothalamic mPGES-1 protein expression in endotoxemic mouse brain 
following VNS 
 
 
 
 
 
 
 
No significant differences were observed in the mPGES-1 expression between SHAM and 
VNS treatments among hippocampus, CC, PAG and DRN, however VNS strongly increased 
mPGES-1 protein level in the hypothalamus of LPS treated mice. (*P<0.05; n= 7; Student’s 
T-test) 
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Study IV  
Immunomodulatory effects of the cholinergic agonist nicotine on activated 
human astrocytes - role of PGE2  
Endotoxemia has been associated with increased IL-1b and IL-6 release by activated 
astrocytes in the hypothalamus (131). Interestingly, activation of the CAP by electrical 
stimulation of the vagus nerve increases brain ACh levels mediated by the adrenergic 
activation of the central cholinergic network (54) and has been shown to reduce 
neuroinflammation (126). Binding of ACh to its nicotinic receptor (a7 in particular) on innate 
immune cells of CNS such as microglia has anti-inflammatory and neuroprotective effects 
(34). On the other hand, such cholinergic effects on astrocytes, most abundant glial cells, 
remains unclear. Suppressive effects of VNS on neuroinflammation (54), co-localization of 
mPGES-1 and GFAP in VNS treated brain regions (Study III), interdependence between 
cholinergic and PGE2 systems (Study I) motivated us to study the effects of nicotine on IL-1b 
activated human astrocytes and role of PGE2 in the cholinergic immune modulation of 
neuroinflammatory events in vitro. 
Over 90% of the cultured human astrocytes grown in vitro displayed strong GFAP 
expression. Activation of 80-90% confluent, serum starved human astrocytes with 
recombinant IL-1b (10ng/ml) induced IL-6, TNFa and IL-8 production. IL-1b neither 
induced Th2 cytokine release nor affected IL-10 levels in culture supernatants. Interestingly, 
in line with previous observations, simultaneous treatment of human astrocytes with IL-1b  
and nAChR agonist, nicotine (1, 10 or 100µM) for 20 hours significantly downregulated IL-
1b induced IL-6 levels. In addition, high dose of nicotine (100µM) also limited the 
production of other crucial mediators of inflammation such as TNFa, IL-1b and IL-8 
respectively. We propose that nicotine executes its effects through a7nAChR whose 
expression was evidently detected on activated astrocytes.  
Acetylcholine esterase (AChE) expression is usually detected in neurons and barely 
expressed in astrocytes except astrocytic tumors (132, 133). In line with this, we did not 
detect any measureable levels of AChE expression in activated human astrocytes. In contrast, 
butyrylcholinesterase (BuChE) is closely associated with inflamed astrocytes and inhibitory 
effects of ACh on BuChE are reported (134). In line with previous reports(135), we found 
that high dose of nicotine reduced BuChE protein synthesis by activated astrocytes.  
Upregulation of COX-2 enzyme and subsequent release of PGE2 in response to nicotine is 
documented in microglia, monocytes and other immune cells (108, 136). In vitro studies by 
Takahashi et al (136) in activated monocytes attributed the beneficial effects of nicotine to 
COX-2 dependent PGE2 release and subsequent EP2/4 receptor activation resulting in high 
concentrations of the secondary messenger, cAMP. In concordance with previous studies on 
microglia (108), COX-2 inhibition by NS-398 treatment reversed immunoregulatory effects 
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of nicotine on activated human astrocytes with respect to IL-6 production as clearly shown in 
Figure 11. 
These results thus confirm the possible beneficial effects of cholinergic activation of nicotinic 
receptors on neuroinflammation driven by activated astrocytes. Furthermore, they reveal the 
cross-talk that exists between cholinergic and prostaglandin systems during immune 
regulation as illustrated in Figure 12 and 13.  
 
Figure 11. Effect of COX-2 inhibition on the nicotine induced IL-6 reduction in 
activated human astrocytes 
 
 
 
 
 
 
 
 
 
 
 
 
Cyclooxygenase-2 activity in human astrocytes was inhibited by using NS-398 (1 and 
10µM). Nicotine treatment significantly downregulated IL-6 release by activated astrocytes. 
Intriguingly, NS-398 completely blocked IL-1b induced PGE2 synthesis and reversed the 
immunomodulatory effects of nicotine on IL-6 release. COX-2 inhibitor did not elicit any 
effects on IL-6 production on its own. All values are represented as mean±SEM in terms of 
fold change compared to cytokine level following IL-1β treatment.  Statistical analysis was 
performed using non-parametric Student t-test (**** (p<0.0001) & ** (p<0.01))  
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Figure 12. Schematic representation of the central effects of VNS on endotoxemic 
mouse brain 
 
Acute VNS strongly activated specific regions of the brain such as hippocampus and 
hypothalamus and increased hypothalamic mPGES-1 protein expression in mice with 
systemic inflammation. On the contrary, VNS did not alter COX-1/2 expression. mPGES-1 
expression co-localized with GFAP+ astrocytes in specific regions of brain including the 
hypothalamus. Interestingly, stimulation of vagus nerve resulted in suppression of substance 
P expression in specific regions of the brain including PAG. 
 
 
 
 
 
 
 
 
Electrical stimulation  
of vagus nerve 
c-Fos mPGES-1 Substance P 
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Figure 13. Schematic representation of the role of PGE2 in mediating the 
immunomodulatory effects of nicotine during reactive astrogliosis. 
 
 
 
Neuroinflammatory responses involving cytokines such as IL-1β upregulate NF-kB activity 
and promote NF-kB dependent cytokine production such as IL-6, TNF-α etc. In our study, 
nicotine inhibited production of IL-1β stimulated inflammatory cytokines through COX-2 
pathway to restore homeostasis. Binding of nicotine to its α7nACh receptor on reactive 
astrocytes increases COX-2 dependent PGE2 release that seems to be a crucial mechanism in 
mediating cholinergic immunomodulation.  
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5 GENERAL DISCUSSION  
The classical lipid mediator, PGE2, has been linked to multiple pathological processes 
involved in acute and chronic inflammatory diseases (137). Of the three terminal synthases 
known, mPGES-1 is mainly responsible for PGE2 upregulation and subsequent trafficking of 
innate immune cells at the inflamed site during the initial phase of inflammation (87). 
Numerous in vivo and in vitro studies have demonstrated the beneficial outcomes associated 
with reduced mPGES-1 activity in controlling inflammation (90, 138). Thus, 
pharmacological inhibition of mPGES-1 is looked upon as a promising strategy for treating 
inflammatory conditions and efforts are underway to develop specific mPGES-1 inhibitors 
(88). At the same time, considerable number of studies have emerged in the recent past 
focusing on the importance of PGE2 in regulating immune responses and initiating resolution 
of inflammation (94, 95, 102, 139). 
Strong evidence has emerged advocating the precedence of high levels of PGE2 to induction 
of special pro resolving mediators (SPMs). SPMs such as lipoxins, resolvins and protectins 
have been identified to be instrumental in orchestrating the series of events leading to 
resolution of inflammation (97). Detailed studies in mice have implicated PGE2 to activate the 
transcription of SPMs, thereby driving the lipid mediator switch from the production of 
proinflammatory leukotrienes (LTB4) to pro resolving mediators (140). Intriguingly, Mikaraj 
et al, clearly demonstrated the link between vagus nerve and SPMs where vagotomy 
increased the proinflammatory cytokines, reduced the levels of pro resolving mediators and 
delayed the resolution of inflammation (141). In this context, the failure of VNS to limit the 
production of LPS induced proinflammatory cytokines in serum and spleen following 
mPGES-1 gene deletion (Study 1) provides convincing evidence in support of the 
importance of PGE2 in vagus nerve mediated resolution.  
ACh producing T cells are critical for functioning of the distal part of CAP (25) and 
activation of EP4, one of the four PGE2 receptors, has been illustrated to increase ChAT 
mediated ACh release in activated human leukemic T cells (110). Abolishment of VNS 
induced ACh release in mPGES-1 depleted mice (Study 1) further confirms the crucial role 
of PGE2 on release of ACh upon cholinergic nerve stimulation. Interestingly, therapeutic 
effects of cholinergic and adrenergic drugs in reducing intraocular pressure in glaucoma 
patients are attributed to PGE2 (142). PGE2 involvement in cholinergic mechanisms is also 
extended to ACh induced smooth muscle contraction where use of NSAIDS inhibited 
nicotine/ACh induced guinea-pig ileum contractions and reversed by PGE2 replenishment 
(143). Intriguingly, anti-inflammatory effects of nicotine have also been shown to be 
mediated through COX-2/PGE2 induction (136, 144). Our observations reiterate the 
participation of PGE2 in executing nicotine immunomodulatory effects in activated immune 
cells both in mice and humans and further uncover the previously unknown involvement of 
mPGES-1 in mediating PGE2 effects on cholinergic immune regulation (Study II).  
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Parallel to the suppressive effects of efferent CAP in the periphery, studies have proposed the 
possibility of an afferent CAP mechanism in the CNS where a7nAchR activation on 
inflamed microglia reduced its cytokine release (35, 54, 145-147). Interestingly, induction of 
acute hypoxic insult in near-term ovine fetus increased vagal activity and a7nAchR 
expression leading to decreased HMGB1 translocation in activated microglia in specific 
regions of the brain (148). Further evidence stems from Meneses et al, where they 
demonstrated the therapeutic ability of VNS in limiting brain cytokine release and microglial 
Iba-1 expression in endotoxemic mice (149). Fresh evidence supporting the existence of an 
afferent CAP is provided by the activation of specific regions such as hippocampus and 
hypothalamus in mouse brain following acute VNS (Study III). 
The fact that VNS upregulated mPGES-1 in hypothalamus (Study III) is in line with reports 
by Schweighögfer et al demonstrating VNS mediated downregulation of hypothalamic IL-6 
and CXCL1 mRNA expression in LPS treated mouse brain (126). Together with the reported 
upregulation of hypothalamic IL-6 levels in LPS injected mPGES-1 (-/-) mouse (150, 151). 
These data signify a possible protective role of mPGES-1 dependent PGE2 on the LPS 
induced proinflammatory cytokine expression in mouse brain. Furthermore, co-localization 
of mPGES-1 and GFAP in hypothalamus implicates astrocytes to be a potential source of 
PGE2 synthesis in response to VNS. We also touched upon the overall effects of COX 
mediated PGs on neuroinflammation where, in support of Blais et al (152), COX inhibition 
enhanced the neuroinflammatory cytokine release triggered by systemic endotoxin. However, 
we have not yet studied the effects of specific mPGES-1 inhibition in this context and the 
exact mechanisms of mPGES-1 in mediating the cholinergic effects of CAP on 
neuroinflammation need further investigation. 
Cholinergic deficit is one of the main pathological consequence of Alzheimer’s disease and 
enhancing cholinergic levels in AD patients has been shown to slow the disease progression 
(151, 153). Interestingly, observational studies in an elderly cohort linked heavy long term 
use of NSAIDS to increased incidence of dementia and AD (154) and further investigations 
are carried out to understand the underlying mechanism. Neuroprotective effects of nicotine 
in reducing Ab accumulation, inhibiting NF-kB in mice (155) and limiting TNFa release by 
activated microglia (145) make it a potential therapeutic agent in alleviating AD progression. 
Nicotine exerted similar inhibitory effects on NFkB dependent cytokines released by reactive 
human astrocytes and most importantly, its limiting effects on IL-8, a neutrophil 
chemoattractant, marks the beginning towards resolution. In support of previous studies on 
PGE2 dependent cholinergic mechanisms in the periphery and microglia (108, 136), use of 
COX-2 inhibitors (NS-398) had detrimental effects on nicotine’s immunosuppression of 
reactive astrocytes (Study IV). PGE2, thus, acts as crucial mediator in the use of cholinergic 
agents to reduce astrogliosis and control neuroinflammation. Whether NSAIDS or mPGES-1 
inhibition can interfere the beneficial effects of VNS on neuroinflammation needs to be 
investigated.  
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There is growing body of evidence against COX/PGE2 inhibition during inflammation 
claiming that these therapies might result in delaying the resolution process of self-limited 
inflammation (97-99). Use of NSAIDS stretched the time to resolve inflammation following 
tooth extraction (156) and impaired healing of gastric ulcers (157). This observation is not 
only restricted to acute inflammation but also seen in various chronic inflammatory 
conditions where COX inhibition affected resolution in murine collagen induced arthritis 
(98). COX-2 has also been illustrated to take part in the resolving acute inflammation in the 
brain (152), lung (158), liver (159) and colon (160) respectively. In a clinical study, use of 
NSAIDS did not improve the pannus formation in joints among patients suffering acute flare 
and remission (99). Interestingly, compared to short term users, long term use of diclofenac in 
patients was associated with increase of osteoarthritic damage in their hips and knee (78). 
Furthermore, inflammatory bowel disease relapsed in 40 % and 70 % of the patients within 
six weeks of coxib and celecoxib treatment (161). Similarly, 17-28 % of patients with 
Crohn’s disease experienced a relapse after 4 weeks of NSAIDS (162). Oral dose of 
ibuprofen in human subjects taking a single session of resistance exercise not only inhibited 
the induction of PGs and leukotrienes post exercise, but also limited the generation of pro 
resolving mediators (163), thus explaining the ineffective muscle recovery in response to 
NSAIDS treatment. Several clinical studies have also reported the detrimental effects of 
NSAIDS on bone healing (80, 81). These observations thus urge us to revisit the role of 
NSAIDS in inflammation and their importance in programming resolution.  
On the other hand, cholinergic mechanisms are proved to regulate cytokine production 
through multiple anti-inflammatory pathways and confer protection against uncontrolled 
inflammation (31, 38, 164). This has made VNS and other cholinergic agonists a promising 
therapy for a range of inflammatory diseases such as sepsis (39), ischemia (165, 166), 
pancreatitis, Alzheimer’s(151), stroke(167) etc . Recent clinical trials on VNS in patients 
suffering from RA(64) and Crohn’s disease (168) led to significant cytokine reduction and 
alleviated the disease severity towards remission. Intriguingly, the response rates were ~70 % 
in both types of patients. Having said that, recent findings of reduced pro resolving mediator 
synthesis and delayed resolution in vagotomized mice demand a deeper understanding of the 
cholinergic anti-inflammatory pathway and its effects on other biological systems can help us 
to develop a better therapeutic strategy. In line with this, our experiments shed light on the 
importance of PGE2 in the optimal functioning of CAP and provide new knowledge on 
possible PGE2-cholinergic cross talk in mediating immune regulation. We firmly believe that 
our study can serve as a model for expanding our knowledge on the role of prostaglandins in 
the underlying mechanisms and possible implications on VNS or specific alpha 7 nicotinic 
agonist therapies in treating diseases. Moreover, the role of PGE2 in cholinergic signaling is 
largely unknown, and further knowledge may lead to alternative ways of activating the CAP, 
as well as more information on potential unwanted effects of drugs inhibiting prostaglandin 
formation, i.e. NSAIDs.  
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6 CONCLUSION AND FUTURE PERSPECTIVES 
In this thesis, we have investigated the role of mPGES-1 dependent PGE2 in cholinergic 
immune regulation mediated by CAP activation and cholinergic agents such as nicotine. 
mPGES-1 activity was either abolished by genetic deletion (Study I, II) or suppressed by 
pharmacological inhibition (Study II). Here, we showed the importance of mPGES-1 gene 
expression and subsequent PGE2 production for VNS induced ACh release and subsequent 
optimal CAP functioning in controlling systemic inflammation (Study I). We interestingly 
found that mPGES-1 deficient mice displayed intact NE release in the spleen after activation 
of the CAP, thus confirming that PGE2 does not play an important role for the neurosignaling 
part of the CAP. However, the distal part of the pathway, with the NE acting on T-cells 
stimulating ACh release was not functioning in mPGES-1 deficient mice, indicating that 
PGE2 plays a crucial role in cholinergic synthesis by regulating the ChAT expression in 
immune cells (Study II). Intriguingly, mPGES-1 depletion affected both cholinergic immune 
regulation in both mouse and human immune cells (Study II). Interestingly, activation of 
CAP by VNS induced mPGES-1 expression in hypothalamus (Study III) and indicates a 
potential immunomodulatory role of PGE2 in afferent CAP mechanism. In support of this 
view, suppression of proinflammatory cytokine release by activated astrocytes following 
nicotine treatment was reversed by COX-2/PGE2 inhibition (Study IV).  
Our studies thus help us to improve our understanding concerning the interaction between the 
cholinergic and prostaglandin systems in regulating key innate immune responses and also 
add novelty to the role of mPGES-1 induced PGE2 in resolving inflammation. We firmly 
believe that our findings on the previously unknown functions of PGE2 as a mediator in 
modulating our immune system will contribute towards choice of use of NSAIDS in patients 
receiving VNS treatment for inflammatory conditions and also for those undergoing 
remission. While pharmacological mPGES-1 inhibition has been advocated as a favorable 
therapeutic target to control inflammation, keeping the impact of PGE2 depletion on tissue 
healing in mind (79-81), its impact on the tissue repair and resolution needs to be thoroughly 
investigated.  
Most importantly, apart from providing new insights on PGE2, numerous crucial mechanistic 
and therapeutic questions remain unanswered. To begin with, the source of PGE2 in 
mediating the peripheral effects of CAP is unclear and can be discovered by carrying out 
adoptive bone marrow transfer experiments using mPGES-1 gene deleted mice. Furthermore, 
the effects of VNS on neuroinflammatory cytokines and involvement of mPGES-1 dependent 
PGE2 needs to be elucidated. The expression pattern of EP receptors and their role in PGE2 
mediated immunosuppression is yet to be addressed. Another critical question is the impact 
of mPGES-1 gene deletion on the generation of SPMs and this can be addressed by 
measuring their levels in mouse samples following VNS. Interestingly, given the therapeutic 
effects of VNS in patients with chronic inflammation (64, 168), the effects of mPGES-1 
depletion on chronic inflammatory mice models such as arthritis undergoing VNS needs to be 
explored. Epidemiological studies on the effects of NSAIDS in patients receiving VNS 
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therapy might further expand our knowledge on the anti-cholinergic effects of NSAIDS on 
inflammation.  In addition, studies of NSAIDs and mPGES-1 inhibitor effects in this context 
may expand our current knowledge on the exact mechanisms of action of these drugs, as well 
as confer new data on their specific interaction with cholinergic immune regulation.  
In conclusion, both our in vitro and in vivo data show that PGE2 has a crucial role in 
cholinergic immune regulatory mechanisms. 
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